Plain-English translation of NCT03131531 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a registry study — meaning researchers are collecting medical records and biological samples from patients with lymphoid cancers to create a database for future research. The goal is to understand how patients respond to different treatments, including new drugs, and to learn more about why some patients' cancers come back or don't respond to standard therapy. By pooling information from many patients, researchers hope to improve treatment options for everyone.
Even though treatments for lymphoid cancers have improved over the past 10 years, many patients still face challenges: some cancers don't respond to standard treatments, others come back after remission, and doctors need more real-world information about how new drugs actually perform outside of controlled clinical trials. This registry will help researchers understand these patterns and develop better strategies.
You likely qualify if…
You likely don't qualify if…
As a participant, you would allow the research team to access your medical records and collect biological samples (such as blood or bone marrow specimens) that are stored in a secure biobank. The study team will track your treatment history and outcomes over time. You would be part of a large group of up to 6,000 patients whose information helps researchers identify patterns in how lymphoid cancers develop and respond to treatment.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
Italy
Sponsor
A.O. Ospedale Papa Giovanni XXIII
Enrollment target
~6,000 participants
Started
March 2017
Primary completion
March 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Alessandro Rambaldi, MD
A.O. Ospedale Papa Giovanni XXIII
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.